Search results for N-terminal

Anti-GPCR LGR6 antibody - N-terminal, Abcam, AB188961

Anti-GPCR TAS1R2 antibody - N-terminal, Abcam, AB150495

Anti-GPR176 antibody [EPR13983] - N-terminal, Abcam, AB184558

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-GRID2 antibody [EPR15422] - N-terminal, Abcam, AB198499

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-PP11 antibody [EPR15137] - N-terminal, Abcam, AB185209

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-PRMT7 antibody [EPR13489] - N-terminal, Abcam, AB179822

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-Peregrin/BRPF1 antibody - N-terminal, Abcam, AB226909

Anti-ARH antibody [EPR13115] - N-terminal, Abcam, AB181043

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-CD74 antibody [2D1B3] - N-terminal, Abcam, AB181465

Anti-CDKN2A/p16INK4a antibody - N-terminal, Abcam, AB189034

Product Specifications Anti-CDKN2A/p16INK4a antibody - N-terminal (ab189034) is a rabbit polyclonal antibody and is validated for use in ICC/IF, IHC-P, WB in human, mouse samples. Anti-CDKN2A/p16INK4a antibody - N-terminal (ab189034) specifically detects CDKN2A/p16INK4a (UniProt ID: P42771; Molecular weight: 17kDa) and is sold in 50 µL selling sizes. Quality and Validation Abcam's high quality validation processes ensure Anti-CDKN2A/p16INK4a antibody - N-terminal (ab189034) has high sensitivity and specificity. Anti-CDKN2A/p16INK4a antibody - N-terminal (ab189034) has been cited over 72 times in peer reviewed journals and is trusted by the scientific community. Anti-CDKN2A/p16INK4a antibody - N-terminal (ab189034) has 4 independent reviews from customers. Target Information CDKN2A, also known as cyclin-dependent kinase inhibitor 2A, is a crucial tumor suppressor gene located on chromosome 9p211. It encodes two proteins, p16INK4a and p14ARF, both of which play significant roles in regulating the cell cycle. p16INK4a inhibits cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), preventing the progression from the G1 to S phase of the cell cycle. This inhibition is vital for controlling cell proliferation and preventing tumor growth. Mutations or deletions in CDKN2A are frequently associated with various cancers, including melanoma, pancreatic cancer, and head and neck squamous cell carcinoma.